Total Payments
$1.9M
2024 Payments
$193,467
Companies
80
Transactions
2,566
Medicare Patients
2,442
Medicare Billing
$436,433
Payment Breakdown by Category
Other$1.5M (77.2%)
Travel$219,835 (11.4%)
Consulting$171,251 (8.8%)
Food & Beverage$43,920 (2.3%)
Research$3,723 (0.2%)
Education$1,897 (0.1%)
Gifts$25.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 506 | 76.8% |
| Travel and Lodging | $219,835 | 578 | 11.4% |
| Consulting Fee | $171,251 | 110 | 8.8% |
| Food and Beverage | $43,920 | 1,345 | 2.3% |
| Honoraria | $9,138 | 6 | 0.5% |
| Unspecified | $3,723 | 3 | 0.2% |
| Education | $1,897 | 17 | 0.1% |
| Gift | $25.00 | 1 | 0.0% |
Payments by Type
General
$1.9M
2,563 transactions
Research
$3,723
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $657,613 | 544 | $0 (2024) |
| Lilly USA, LLC | $283,255 | 324 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $273,891 | 207 | $0 (2024) |
| Incyte Corporation | $142,467 | 128 | $0 (2024) |
| Merck Sharp & Dohme LLC | $99,594 | 191 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $71,665 | 74 | $0 (2024) |
| PFIZER INC. | $67,101 | 122 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $60,123 | 64 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $58,561 | 100 | $0 (2024) |
| GENZYME CORPORATION | $36,134 | 35 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $193,467 | 322 | JAZZ PHARMACEUTICALS INC. ($96,345) |
| 2023 | $255,982 | 279 | JAZZ PHARMACEUTICALS INC. ($72,638) |
| 2022 | $221,106 | 282 | E.R. Squibb & Sons, L.L.C. ($54,687) |
| 2021 | $310,946 | 285 | E.R. Squibb & Sons, L.L.C. ($81,599) |
| 2020 | $127,732 | 160 | E.R. Squibb & Sons, L.L.C. ($63,701) |
| 2019 | $270,163 | 415 | E.R. Squibb & Sons, L.L.C. ($95,970) |
| 2018 | $225,928 | 357 | E.R. Squibb & Sons, L.L.C. ($84,674) |
| 2017 | $330,528 | 466 | E.R. Squibb & Sons, L.L.C. ($175,292) |
All Payment Transactions
2,566 individual payment records from CMS Open Payments — Page 1 of 103
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $26.63 | General |
| 12/23/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Oncology | ||||||
| 12/23/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Oncology | ||||||
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $6.29 | General |
| Category: Oncology | ||||||
| 12/18/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $620.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/18/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $19.00 | General |
| 12/16/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $6.26 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $4.67 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Oncology | ||||||
| 12/12/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $9.88 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Consulting Fee | Cash or cash equivalent | $8,240.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $12.03 | General |
| 12/09/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $6.06 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.68 | General |
| Category: Oncology | ||||||
| 12/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $6.89 | General |
| Category: Oncology | ||||||
| 12/06/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $4.20 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: Iron Deficiency Anemia | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 4400 - CFZ Ph1b/2 SCLC (CFZ004) | Amgen Inc. | $3,500 | 1 |
| A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION | Eli Lilly and Company | $190.25 | 1 |
| A RANDOMIZED PHASE 3 STUDY OF LY2835219 PLUS BEST SUPPORTIVE CARE VERSUS ERLOTINIB PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH STAGE IV NSCLC WITH A DETECTABLE KRAS MUTATION WHO HAVE PROGRESSED AFTER PLATINUM BASED CHEMOTHERAPY | Eli Lilly and Company | $32.85 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 514 | 907 | $233,015 | $84,588 |
| 2022 | 6 | 560 | 1,134 | $275,373 | $112,729 |
| 2021 | 9 | 645 | 1,208 | $280,232 | $124,284 |
| 2020 | 10 | 723 | 1,284 | $302,641 | $114,832 |
Total Patients
2,442
Total Services
4,533
Medicare Billing
$436,433
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 296 | 583 | $141,669 | $50,265 | 35.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 58 | 111 | $38,073 | $14,539 | 38.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 43 | $16,297 | $5,626 | 34.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 84 | $11,508 | $5,065 | 44.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $14,628 | $4,973 | 34.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,736 | $2,669 | 39.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $3,108 | $1,204 | 38.7% |
| 99422 | Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | Office | 2023 | 12 | 12 | $996.00 | $246.07 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 316 | 676 | $145,926 | $59,069 | 40.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 80 | 242 | $70,336 | $30,922 | 44.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 46 | $17,734 | $6,712 | 37.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 37 | 37 | $14,767 | $6,168 | 41.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $14,722 | $5,321 | 36.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 37 | 86 | $11,888 | $4,537 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 327 | 643 | $129,886 | $58,076 | 44.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 96 | 288 | $78,624 | $38,198 | 48.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 44 | 49 | $19,061 | $7,525 | 39.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 45 | 45 | $17,595 | $7,187 | 40.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 48 | 48 | $14,880 | $5,745 | 38.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 33 | 71 | $9,869 | $3,695 | 37.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 23 | $4,600 | $1,790 | 38.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 19 | 20 | $2,840 | $1,124 | 39.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 21 | $2,877 | $945.09 | 32.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 294 | 537 | $108,474 | $40,718 | 37.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 108 | 337 | $92,001 | $34,724 | 37.7% |
About Dr. Firas Badin, M.D
Dr. Firas Badin, M.D is a Internal Medicine healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1588828693.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Firas Badin, M.D has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $193,467 received in 2024. These payments were reported across 2,566 transactions from 80 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Badin has provided services to 2,442 Medicare beneficiaries, totaling 4,533 services with total Medicare billing of $436,433. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Lexington, KY
- Active Since 07/17/2008
- Last Updated 12/09/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588828693
Products in Payments
- OPDIVO (Biological) $640,347
- ZEPZELCA (Drug) $273,891
- JAKAFI (Drug) $139,407
- LIBTAYO (Biological) $100,926
- KEYTRUDA (Biological) $87,219
- CYRAMZA (Drug) $80,919
- RETEVMO (Drug) $61,649
- ELIQUIS (Drug) $55,985
- GILOTRIF (Drug) $54,282
- ALIMTA (Drug) $48,938
- TEPMETKO (Drug) $30,920
- LUMAKRAS (Drug) $27,063
- CALQUENCE (Drug) $26,363
- JAYPIRCA (Drug) $15,296
- IMFINZI (Drug) $15,034
- Vitrakvi (Drug) $13,180
- TECENTRIQ (Biological) $10,632
- BRAFTOVI (Drug) $9,784
- TAGRISSO (Drug) $9,417
- ALUNBRIG (Drug) $8,206
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Lexington
Dennis Doherty, Md, MD
Internal Medicine — Payments: $686,622
Internal Medicine $686,622
Dr. Robert Sawyer, M.d, M.D
Internal Medicine — Payments: $232,104
Internal Medicine $232,104
David Mannino, Md, MD
Internal Medicine — Payments: $140,029
Internal Medicine $140,029
Dr. Anastasia Jandes, Md, MD
Internal Medicine — Payments: $90,742
Internal Medicine $90,742
Gloria Vigliani, M.d, M.D
Internal Medicine — Payments: $89,452
Internal Medicine $89,452
David Moliterno, Md, MD
Internal Medicine — Payments: $76,038
Internal Medicine $76,038